1152.75 64.00 (5.88%)

595.68% Gain from 52W Low

656.0K Volume

NSEJan 20, 2021 03:31 PM



Mastek Ltd.    
29 Dec 2020
1152.75
5.88%
buy
ICICI Securities Limited
Rising adoption of smartphones, high internet speed and social distancing (due to Covid-19) has changed consumer behaviour. Consumers now prefer to transact (buy a product) virtually over the smartphone via an app instead of physical transaction. This has led to virtualisation of business models. In addition, to keep business up and running in a work from home scenario, technology is gaining traction. As a result, new age technologies like cybersecurity (to protect business from work from home scenario), app development (to help customer transact virtually) and Cloud (to enable...
Mastek Ltd. has gained 171.75% in the last 6 Months
Mastek Ltd.    
31 Oct 2020
1152.75
5.88%
buy
ICICI Securities Limited
Revenue in the quarter was driven by UK government and US retail. While the UK private sector was flat in the current quarter, Mastek believes the UK private sector has bottomed out. Hence, with traction in UK government revenues, US retail and UK private sector, we expect the company to register improving revenues in coming quarters. In addition, Evosys expertise in Oracle cloud migration coupled with Mastek's capability to cross-sell data analytics, application support and digital commerce will help the company win integrated and larger deals. This will result in multi-million...
Mastek Ltd. has gained 160.77% in the last 1 Year
Mastek Ltd.    
30 Oct 2020
1152.75
5.88%
buy
Sharekhan
We recommend a Buy rating on Mastek Limited with a price target (PT) of Rs. 1,040 as risk-reward balance remains favourable. Company delivered a strong set of numbers in Q2FY21, led by strong growth in both the UK and US businesses and accelerated growth in the Oracle services business; EBITDA margin expanded by 348 bps q-o-q to 21.1%; order-booking grew 22% q-o-q. Management expects H2FY2021 to be better than H1FY2021, led by a strong order book, continued growth in UK government projects and higher demand for cloudrelated services; Evosys order-book was up by over 65% y-o-y The stock is trading at a reasonable valuation of 10x its FY2023E EPS; net cash...
default
Mastek Ltd. is trading above it's 200 day SMA of 680.0
Mastek Ltd.    
30 Oct 2020
1152.75
5.88%
buy
Sharekhan
We recommend a Buy rating on Mastek Limited with a price target (PT) of Rs. 1,040 as risk-reward balance remains favourable. Company delivered a strong set of numbers in Q2FY21, led by strong growth in both the UK and US businesses and accelerated growth in the Oracle services business; EBITDA margin expanded by 348 bps q-o-q to 21.1%; order-booking grew 22% q-o-q. Management expects H2FY2021 to be better than H1FY2021, led by a strong order book, continued growth in UK government projects and higher demand for cloudrelated services; Evosys order-book was up by over 65% y-o-y The stock is trading at a reasonable valuation of 10x its FY2023E EPS; net cash...
Mastek Ltd. has gained 42.76% in the last 3 Months
Mastek Ltd.    
31 Jul 2020
1152.75
5.88%
HDFC Securities
Max Financial: Despite a difficult environment, MAXL delivered an APE decline of just 3.5% YoY. The margin was 250bps YoY lower mainly due to an increase in reinsurance costs, which the company has passed on 2QFY20 onwards. We expect the margin to improve hereon. We believe the deal with AXSB will provide long-term distribution capability. We expect an FY21-23E APE/VNB CAGR of 12.6/16.2%. We retain our ADD rating with an unchanged target price of Rs 645 (FY21E EV + 21.3x FY22E VNB). Navin Fluorine International: We retain our ADD rating on NFIL with a target price of INR 1,840 on the back of (1) earnings visibility given long term contracts, and (2) tilt in sales mix towards customised products. The stock is currently trading at 22.5x FY23E EPS, which is contextually low, given the RoIC of 21.6/24.2% in FY22/23E. Mastek: Mastek delivered strong revenue and margin performance led by full quarter integration of Evosys. Mastek organic business was down 4.4% QoQ due to weakness in UK private (-6.5% QoQ, Retail+BFS) and US Retail portfolio offset by strong UK Govt. (+13.9% QoQ). The UK Govt. will continue to perform well given Mastek's strong relationship, integration of Evosys capabilities, and revival of UK Govt spending. The UK private sector is facing the dual impact of Brexit and Covid-19 and will remain under stress. US revenue is impacted by Retail slowdown and recovery will be protracted. EBIT Margin expanded 321bps YoY to 14.7% led by the integration of high margin Evosys business. Evosys has performed well (+10% QoQ), driven...
Mastek Ltd.'s price crossed above SMA50 today
Mastek Ltd.    
31 Jul 2020
1152.75
5.88%
buy
ICICI Securities Limited
Organic revenues are expected to be impacted by a ramp down by customers in UK private retail & financial services and pricing pressure in US retail partly offset by higher growth from UK government business. However, vendor consolidation opportunity in US retail and integrated offering of Evosys & Mastek is expected to boost the topline. There is a significant shift of enterprise towards cloud migration and Evosys expertise in Oracle cloud migration is gaining traction. This coupled with Mastek's capability to cross-sell data analytics, application support and digital...
Mastek Ltd. has an average target of 1275.00 from 3 brokers.
Mastek Ltd.    
16 Jun 2020
1152.75
5.88%
HDFC Securities
Our TP of Rs 400 is based on 7x FY22E EPS plus Rs 36/sh for ~5% stake in Majesco US. Maintain BUY. Mastek delivered strong revenue and margin performance led by the integration of Evosys. Mastek organic growth (+1.1% QoQ) was inline led by traction in UK Govt. (+6.9% QoQ CC) offset by weakness in UK private (Covid+Brexit) and US (-18.5% QoQ CC). Weakness in US (Retail) and UK Private (Retail+BFS) will impact Mastek organic growth in FY21E. Margin expansion (+349bps QoQ) in the quarter was led by the integration of high margin Evosys business. We assume Evosys revenue of USD 63mn and ~19% EBITDA margin for FY21E. We cut our USD revenue estimate by 4.1/3.6% for FY21/22E due to high exposure to Retail (~22% of rev) and Covid-19 uncertainty. We increase our EPS estimate by 13.1/19.4% for FY21/22E to factor in higher-margin Evosys integration and currency tailwind
Mastek Ltd. has gained 171.75% in the last 6 Months
Mastek Ltd.    
16 Jun 2020
1152.75
5.88%
buy
ICICI Securities Limited
The company's organic revenues in the near term are expected to be under pressure led by a ramp down by customers in UK private retail & financial services and deferral of sales to later part of the year. In addition, the US geography, which is primarily focused on the retail sector, faced a delay in projects and pricing pressure, which is further expected to impact organic revenues. However, the acquisition of Evosys, vendor consolidation opportunity in US retail and higher sales pipeline in UK government are expected to drive overall revenues in FY21E. We expect FY21E revenues to...
Mastek Ltd. is trading above it's 200 day SMA of 680.0
Mastek Ltd.    
11 Feb 2020
1152.75
5.88%
buy
ICICI Securities Limited
Evosys is focused on Oracle cloud implementation and consultancy. It provides a gamut of solution offerings like Oracle HCM Cloud, Oracle ERP Cloud, Oracle SCM Cloud, Oracle CX, Oracle EPM Cloud, PaaS solutions (including custom-built solutions), AI, IoT and machine learning. The company generates 60% of revenues from Oracle cloud implementation, 32% from support services and rest from licence revenues. Geography wise, the company generates 44% of revenues from Middle East, 17% from North America, 30% from the US, UK and the rest from APAC region. Further, the...
Mastek Ltd. has gained 171.75% in the last 6 Months